Protocolo de Actuación en Mieloma múltiple - Sociedad Asturiana ...

14. Palumbo A, Bringhen S, Caravita T, et al. Italian Multiple
Myeloma Network, GIMEMA. Oral melphalan and prednisone chemotherapy plus
thalidomide compared with melphalan and prednisone alone in elderly patients with multiple
myeloma: randomised controlled trial. Lancet 2006;11: 825-31
15. Palumbo A, Bringhen S, Cavalli M et al. Bortezomib, Melphalan, Prednisone and
Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for
Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of
Prognostic Factors. Blood 2010; 116 (abst. 620)
16. Palumbo A, Zdenek A, Kropff et al. A phase 3 study evaluating the efficacy and safety of
lenalidomide combined melphalan and prednisone followed by continous lenalidomide
maintenance (MPR-R) in patients ≥ 65 years with newly diagnosed multiple myeloma: Update
results for aged 65-75 years enrolled in MM-015. Blood 2011; 118 (abst.475)
17. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med 2011; 364: 1046-60
18. Palumbo A, Bringhen S, Ludwig H et al. Personalized therapy in multiple myeloma according
to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood
2011; 118: 4519-4529
19. Pönisch W, Mitrou PS, Merkle K, Herold M, Assmann M, Wilhelm G, Dachselt K, Richter P,
Schirmer V, Schulze A, Subert R, Harksel B, Grobe N, Stelzer E, Schulze M, Bittrich A,
Freund M, Pasold R, Friedrich T, Helbig W, Niederwieser D. Treatment of bendamustine and
prednisone in patients with newly diagnosed multiple myeloma results in superior complete
response rate, prolonged time to treatment failure and improved quality of life compared to
treatment with melphalan and prednisone--a randomized phase III study of the East German
Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol. 2006;
132(4):205-12
20. Rajkumar SV, Jacobus S, Callander N et al. Lenalidomide plus high dose dexametasona vs
lenalidomide plus low dose dexametasona as initial therapy for newly diagnosed multiple
myeloma: an oplel-label randomised controlled trial. Lancet Oncol 2010; 11: 29-37
21. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I,
Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang
B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson
PG; VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial
treatment of multiple myeloma. N Engl J Med. 2008; 359(9):906-17
22. San Miguel JM, Schlag R, Khuageva N et al. VMP vs MP in patients with previously
untreated multiple myeloma and no increased risk of second primary malignancies: Final
results of the phase 3 VISTA trial. Blood 2011; 118 (abst.476)
23. Vesole DH, Jacobus S, Rajkumar SV et al. Lenalidomide plus lose doses dexametasone
superior one and two year survival regardless of age compared to lenalidomide plus highdoses
dexametasone. Blood 2010; 116. (abst. 308)
24. Wijermans, Schaafsma M, van Norden Y, Ammerlaan R, Wittebol S, Sinnige H el al.
Melphalan+prednisone versus Melphalan+prednisone+thalidomide in induction therapy for
multiple myeloma in elderly patients: Final analysis of the Dutch cooperative Group HOVON
49 study. Blood 2008; 112 (abst.649)
Grupo Asturiano de Linfoma y Mieloma
54